Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant ...

If you receive JavaScript required to sign in error message when using Skype, OneDrive, Teams or any other program, you need to turn on or enable JavaScript in your ...

This library serves as a comprehensive reference implementation of MessagePack for JavaScript with a focus on accuracy, compatibility, interoperability, and performance. Additionally, this is also a ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

I’m starting to believe that Conservative Leader Pierre Poilievre is the subject of an elaborate, prolonged hazing ritual.

In many sexually dimorphic species, a mechanism is required to ensure equivalent levels of gene expression from the sex chromosomes. In mammals, such dosage compensation is achieved by X-chromosome ...

Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for ...